MedTrace Logo

PHIL in the Treatment of Intracranial dAVF.

NCT03467542 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2024-12-31

Study results available
· View outcomes & findings →

Summary

This study is a prospective, multicenter, single-arm study. Patients with Dural Arteriovenous Fistulas (dAVF) have a few choice for safe treatment. In this study, all patients with qualifying dAVFs will be treated with PHIL® Liquid Embolic material.

Conditions

  • Arteriovenous Dural Fistula

Interventions

DEVICE

PHIL® Liquid Embolic System

The PHIL Embolic System is indicated in the treatment of dural arteriovenous fistulas (DAVF)

Sponsors & Collaborators

  • Microvention-Terumo, Inc.

    lead INDUSTRY

Principal Investigators

  • J Mocco, MD · Mt. Sinai

  • Alan Boulos, MD · Albany Medical College

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-24
Primary Completion
2022-12-12
Completion
2022-12-12
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03467542 on ClinicalTrials.gov